| scholarly article | Q13442814 |
| P2093 | author name string | B Golding | |
| D E Scott | |||
| H Golding | |||
| L R King | |||
| O Scharf | |||
| D Frazier | |||
| N Eller | |||
| P2860 | cites work | Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 |
| Intravenous immunoglobulins as therapeutic agents | Q33449825 | ||
| beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques | Q33555112 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages | Q33944466 | ||
| Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit | Q34199263 | ||
| Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. | Q34214455 | ||
| Immune Globulins | Q34469675 | ||
| Metabolic properties of IgG subclasses in man | Q35576283 | ||
| Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. | Q35839936 | ||
| Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo | Q35841911 | ||
| Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. | Q35894716 | ||
| Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. | Q35897786 | ||
| Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies | Q35981835 | ||
| Intermolecular cooperativity: a clue to why mice have IgG3? | Q36374229 | ||
| An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 | Q36687524 | ||
| Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody | Q36687562 | ||
| Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses | Q36687749 | ||
| pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-Sepharose | Q39293270 | ||
| Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
| Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. | Q39583017 | ||
| Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo | Q41175109 | ||
| A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope | Q41586283 | ||
| Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis | Q41626651 | ||
| Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody | Q44008306 | ||
| Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). | Q45744567 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. | Q45751388 | ||
| Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group | Q45762210 | ||
| HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees | Q45781750 | ||
| Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors | Q45853207 | ||
| Prevention of HIV infection by passive immunization with HIV immunoglobulin | Q47571809 | ||
| Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. | Q51607032 | ||
| Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG | Q52847434 | ||
| The G4 subclass in IgG fractions prepared by ion-exchange chromatography | Q54423100 | ||
| Correlation between segmental flexibility and effector function of antibodies | Q59069367 | ||
| Antibody–antigen flexibility | Q59071710 | ||
| Differences among available immunoglobulin preparations for intravenous use | Q69033645 | ||
| Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin | Q70691418 | ||
| Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
| Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains | Q72072927 | ||
| IgG Subclasses in Human γ-Globulin Preparations for Intravenous Use and Their Reactivity with Staphylococcus Protein A | Q72610731 | ||
| Papain sensitivity of heavy chain sub-classes in normal human IgG and localizaton of antigenic determinants for the sub-classes | Q93724641 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6558-6565 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. | |
| P478 | volume | 75 |
| Q64063666 | A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress |
| Q33809443 | Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection |
| Q35075147 | Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. |
| Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
| Q36118373 | Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses |
| Q33867299 | Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design |
| Q40621708 | Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals |
| Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
| Q36753653 | Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women |
| Q24562005 | Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations |
| Q35175489 | Class and subclass selection in parasite-specific antibody responses |
| Q39108779 | Complex immune correlates of protection in HIV-1 vaccine efficacy trials |
| Q27490436 | Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype |
| Q40460964 | Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purified human B cells. |
| Q35857221 | Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors |
| Q33764917 | Early development of broadly neutralizing antibodies in HIV-1-infected infants |
| Q35848642 | Effects of adjuvants on IgG subclasses elicited by virus-like particles |
| Q92633061 | Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection |
| Q38692190 | Errors in data interpretation from genetic variation of human analytes |
| Q59350085 | Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques |
| Q83168652 | HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies |
| Q35096836 | HIV-1-specific antibody responses during acute and chronic HIV-1 infection |
| Q34445962 | High-throughput sequencing of human immunoglobulin variable regions with subtype identification. |
| Q89857555 | Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies |
| Q35583369 | Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). |
| Q36859366 | Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection |
| Q34529911 | Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus |
| Q92006869 | IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody |
| Q59354602 | IgG3 regulates tissue-like memory B cells in HIV-infected individuals |
| Q34033051 | Immunity to HIV in Early Life |
| Q34641666 | Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations |
| Q37578785 | Low-affinity Fcgamma receptors, autoimmunity and infection |
| Q45073031 | Molecular evolution of IgG subclass among nonhuman primates: implication of differences in antigenic determinants among Apes |
| Q26825548 | Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases |
| Q34511239 | Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus |
| Q41934634 | Natural Killer cells in HIV-1 infection and therapy |
| Q35888710 | Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control |
| Q27478005 | Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions |
| Q54575753 | Sooty mangabey (Cercocebus torquatus atys) IGHG and IGHA genes. |
| Q37696721 | Structure and function of immunoglobulins |
| Q38848145 | Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI |
| Q38239283 | The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies |
| Q37113972 | The role of Fc receptors in HIV prevention and therapy |
| Q34389587 | Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity |
| Q33977866 | Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination |
| Q37497024 | iTRAQ-Based Proteomics Identification of Serum Biomarkers of Two Chronic Hepatitis B Subtypes Diagnosed by Traditional Chinese Medicine |
Search more.